Albion News

Dysis Imaging
DYSIS Medical Ltd, the developer of the innovative DYSIS Ultra Colposcope used in cervical cancer screening, announced today the appointment of Darin Hammers as Chief Executive Officer and a member of the board of directors. In addition, Michael Gioffredi was appointed as Chief Commercial Officer. Former CEO Alastair Atkinson will remain with the company and assume the role of Chief Operating Officer. “We believe that Mr. Hammers and Mr. Gioffredi have the right leadership experience and knowledge of the U.S. medical device market to establish DYSIS as the leader in Colposcopy. On behalf of... read more
Orchard Therapeutics
UCLTF funded Orchard Therapeutics, a biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, today announced the completion of an oversubscribed $150 million Series C financing.is one of the early Deerfield Management led the financing with significant new investments from RA Capital Management, Venrock, Foresite Capital, Perceptive Advisors, Cormorant Asset Management LP, ArrowMark Partners, Sphera Global Healthcare, Medison Ventures, Driehaus Capital Management and Ghost Tree Capital Group, LP, as well as additional U.S.... read more
uMotif
uMotif, the data capture company putting patients at the centre of clinical research, has raised £2.4 million in its latest funding round led by Albion Capital, the leading independent investment manager, along with several angel investors. uMotif’s software platform provides the patient-facing technology required to capture real-world data (eCOA, ePRo, eConsent) for the next generation of clinical research initiatives – from early phase to post-marketing trials. The technology is already in use by top pharma companies across Europe and North America, including AstraZeneca, Novartis and UCB... read more
Dysis
DYSIS Medical Ltd, the developer of the innovative DYSIS Ultra colposcope used in cervical cancer screening, announces today the completion of an £18 million ($25 million) investment. For the full story please click here read more
MeiraGTx
UCL Technology Fund investment MeiraGTx Holdings plc (‘MeiraGTx’), the clinical stage gene therapy company, has raised $75million at IPO, pricing five million shares at $15.00 per share on the Nasdaq Global Select Market on June 12 2018. The UCL Technology Fund (UCLTF) is managed by Albion Capital in collaboration with UCL Business (UCLB), UCL’s commercialisation company, and is dedicated to bringing UCL’s world-class research in life and physical sciences to commercial reality. MeiraGTx is its first investment to IPO. MeiraGTx has strong roots in UCL; its rare eye diseases business was borne... read more
Healios
Healios, the digital therapy company for mental health, has raised £2.2m ($3m) in its latest funding round, led by investors Albion Capital and Spice Capital. Founded in 2013, Healios empowers young patients and families affected by mental illness and neurodevelopmental conditions through combining the use of technology with specialised clinician expertise and evidence-based clinical tools. Utilising its unique digital platform, Healios enables the efficient delivery of family-centric care, delivering a revolutionary interactive experience across multiple family members. Its technology-driven... read more
Mirada Medical
Optellum (Oxford, UK), a high-tech startup in lung cancer and machine learning and Mirada Medical, an established leader in scientifically advanced quantitative imaging software, are announcing a partnership to accelerate the deployment of deep learning technology to market.  This unique collaboration combines the deep technology and clinical expertise of Optellum with the software platforms and rapid development know-how of Mirada.  They have partnered to address a huge and growing problem in lung cancer diagnosis: the management of patients with indeterminate pulmonary nodules. Early... read more
Albion is deleighted to congratulate Helen Shaw, Director and Co-Founder of Albion portfolio company Proveca, who has been named as one of the Top 50 Movers and Shakers in BioBusiness 2017. 50 Movers and Shakers in BioBusiness 2017 celebrates leaders whose dedication is about innovation in the healthcare business. These are female leaders that have been recognised for the progress they have made over the past year. Their achievements demonstrate expertise in their specialised field, general management skills and an ability to collaborate across disciplines. Diversity of talent is critical to... read more
  Locum’s Nest, a mobile first platform founded by doctors which is revolutionising the way staffing shortages are addressed in the NHS, has completed a £1.1m funding round led by Albion Capital, (‘Albion’), one of the UK’s leading independent investment managers and IDO Investments, an innovation firm based in Oman (‘IDO’). The investment will be used to expand Locum’s Nest nationally and add additional functionality to the service. Locum’s Nest revolutionises the way locum doctors are managed by NHS trusts. The cost of agency locum doctors is one of the most controversial and draining holes... read more
Exco InTouch which is backed by Scottish Equity Partners (SEP) and Albion, has been acquired by ERT, the leading provider of high-quality patient data collection solutions for use in clinical drug development. The acquisition comes on the back of impressive growth for Nottingham based Exco InTouch.  The combined organisation will provide the biopharmaceutical industry with the most advanced and comprehensive choice for electronic clinical outcome assessments (eCOA), patient engagement and digital health supporting the entire clinical development to commercialisation spectrum – from early... read more

Pages